Guideline Video

Guideline Resources

  • Pharmacological Management of United States Adults With Overweight or Obesity
  • The Obesity Society, Obesity Medicine Association, Obesity Action Coalition
  • March 5, 2026
  • Summary
  • Full-text

Video Transcription

Just published March 5th, 2026, The Obesity Society, Obesity Medicine Association, and Obesity Action Coalition’s newest guideline on Pharmacological Management of United States Adults With Overweight or Obesity.

The purpose of this guideline is to provide evidence-based recommendations on pharmacological management of US adults with overweight or obesity. The primary goals are to review, appraise, and support implementation of evidence to maximize benefits, including weight reduction and maintenance of lost weight, improved health outcomes, and quality of life, while minimizing harms including adverse drug reactions, treatment burden, and access inequality.

In today’s rapid update, we’ll just be going over the recommendations so for the full guideline, make sure to check it out on guidelinecentral.com

Let’s get started. 

  • The guideline suggests using orlstat in adults aged 18 years or older with overweight or obesity. 
  • The guideline recommends using bupropion-naltrexone in adults aged 18 years or older with overweight or obesity. 
  • The guideline suggests using phentermine for 3 months or more in adults aged 18 years or older with overweight or obesity. 
  • The guideline suggests using phentermine-topiramate in adults aged 18 years or older with overweight or obesity. 
  • The guideline suggests using liraglutide in adults aged 18 years or older with overweight or obesity. 
  • The guideline recommends using semaglutide in adults aged 18 years or older with overweight or obesity. 
  • The guideline recommends using tirzepatide in adults aged 18 years or older with overweight or obesity. 
  • The guideline recommends using setmelanotide in adults aged 18 years or older with monogenic obesity syndromes. 
  • The guideline recommends continuing obesity medications in adults undergoing medical obesity treatment during the weight maintenance phase, compared with not continuing obesity medications. 
  • The guideline suggests using GLP-1 receptor agonists or GLP-1/GIP receptor dual agonists in adults aged 18 years or older with obstructive sleep apnea. 
  • The guideline suggests using GLP-1 receptor agonists or GLP-1/GIP receptor dual agonists in adults aged 18 years or older with heart failure with preserved ejection fraction. 
  • The guideline suggests using GLP-1 receptor agonists or GLP-1/GIP receptor dual agonists in adults aged 18 years or older to reduce liver fat and treat metabolic dysfunction-associated steatohepatitis. 
  • The guideline suggests using GLP-1 receptor agonists compared to lifestyle interventions/placebo in adults aged 18 years or older with osteoarthritis. 
  • The guideline suggests using semaglutide in adults aged 18 years or older with a history of myocardial infarction, stroke, or symptomatic peripheral vascular disease. 
  • The guideline suggests using FDA-approved obesity medications in adults aged 18 years or older with type 2 diabetes. 

And there you have it. Make sure to check out the full guideline from The Obesity Society, Obesity Medicine Association, and Obesity Action Coalition and other related clinical decision support tools at guidelinecentral.com.

Sign up for alerts and stay informed on the latest published articles and guidelines.